Trials / Unknown
UnknownNCT02602249
Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.
Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With MUC1 Gene(MUC1-gene-DC-CTL) or Directly Pulsed by MUC1 Peptide(MUC1-peptide-DC-CTL) in Gastric Cancer.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Beijing Doing Biomedical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In this study, safety and effects of MUC1-gene-DC-CTL and MUC1-peptide-DC-CTL on human gastric cancer are going to be investigated.
Detailed description
PBMC of the patient will be separated from peripheral blood.DCs infected by MUC1 and pulsed by MUC-1 peptide are made respectively from PBMC, then they are respectively cultured with T cells into MUC1-gene-DC-CTL and MUC1-peptide-DC-CTL which will be infused to the patients as immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MUC1-gene-DC-CTL | MUC1-gene-DC-CTL will be used against tumor cells. |
| BIOLOGICAL | MUC1-peptide-DC-CTL | MUC1-peptide-DC-CTL will be used against tumor cells. |
Timeline
- Start date
- 2017-10-01
- Primary completion
- 2019-04-01
- Completion
- 2020-04-01
- First posted
- 2015-11-11
- Last updated
- 2017-09-05
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02602249. Inclusion in this directory is not an endorsement.